Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis.
Walter MassonAugusto María Lavalle CoboJuan Patricio NogueiraPublished in: Cells (2021)
(1) Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial adipose tissue (EAT) is associated with increased cardio-metabolic risks and obstructive coronary disease events in patients with T2D. (2) We performed a systematic review and meta-analysis of SGLT2-i therapy on T2D patients, reporting data on changes in EAT after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random effects or fixed effects model meta-analysis was then applied. (3) Results: A total of three studies (n = 64 patients with SGLT2-i, n = 62 with standard therapy) were included in the final analysis. SGLT2 inhibitors reduced EAT (SMD: -0.82 (-1.49; -0.15); p < 0.0001). An exploratory analysis showed that HbA1c was significantly reduced with SGLT2-i use, while body mass index was not significantly reduced with this drug. (4) Conclusions: This meta-analysis suggests that the amount of EAT is significantly reduced in T2D patients with SGLT2-i treatment.
Keyphrases
- adipose tissue
- systematic review
- cardiovascular events
- body mass index
- coronary artery disease
- insulin resistance
- high fat diet
- meta analyses
- case control
- ejection fraction
- end stage renal disease
- emergency department
- big data
- heart failure
- metabolic syndrome
- skeletal muscle
- stem cells
- public health
- randomized controlled trial
- peritoneal dialysis
- machine learning
- physical activity
- weight gain
- data analysis
- climate change
- combination therapy
- weight loss
- human health
- artificial intelligence
- left ventricular
- replacement therapy
- aortic stenosis